US biotech fund sees potential in Denmark  

US fund Care Capital eyes investment possibility in Danish biotech company NatImmune

Daily financial newspaper Børsen reports that the US biotechnology foundation Care Capital is close to making its first investment in Denmark. Care Capital has been closely observing the partly Novo A/S owned biotech company NatImmune, which early next year plans to start clinical trials of a drug designed to prevent infections in hospitalised patients with weakened immune defences. The drug is expected to reach the market by 2005, a realistic aim if the drug achieves fast track approval with health authorities.


Care Capital has investment reserves estimated at USD 300 million (DKK 2.5 billion).

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×